Navigation Links
Clinical trial seeks to improve patient treatment for Crohn’s disease
Date:1/4/2010

Robarts Clinical Trials at The University of Western Ontario in London, Canada, has been awarded a 4.7 million dollar grant to conduct a randomized controlled trial evaluating treatment options for Crohn's disease. The outcome is expected to lead to a more streamlined treatment path and better disease management for patients. Abbott, the global health care company, has provided a grant to complete research for the REACT (Randomized Evaluation of an Algorithm for Crohn's Treatment) study.

Crohn's disease is a chronic inflammatory disorder that is characterized by symptoms of diarrhea, abdominal pain and gastrointestinal bleeding. It typically effects younger people and can result in serious complications such as bowel obstruction. Although conventional anti-inflammatory treatments such as prednisone improve symptoms, they are associated with important side effects and are only partially effective. Many patients require surgery to treat the disease.

The REACT study will be carried out at 40 gastroenterology practices in Canada and Belgium. The sites will be randomly assigned to treat patients with Crohn's disease to either a conventional management strategy featuring gradual escalation of drug therapy or a newer paradigm that features early use of combined immunosuppression with a tumor necrosis factor alpha blocking drug and an anti-metabolite.

"This trial builds on the results of recent studies that suggest use of combined therapy early in the course of treatment yields superior long-term results," says Dr. Brian Feagan, the lead investigator for the study. "We are excited about this project since it is the first large-scale, community-based evaluation of this approach. We expect that patients treated with combination therapy will be more likely to enter remission and rates of hospitalization and health-care utilization will be reduced." Dr. Feagan is the Director of Robarts Clinical Trials and a professor in the Department of Medicine at Western's Schulich School of Medicine & Dentistry.


'/>"/>

Contact: Kathy Wallis
kwallis3@uwo.ca
519-661-2111 x81136
University of Western Ontario
Source:Eurekalert

Related medicine news :

1. Michael J. Fox Foundation Awards $2 Million for Clinical Research on Postural Instability and Gait Disturbances in Parkinsons Disease
2. Crohn's & Colitis Foundation Presents National Science Awards to Clinical and Scientific Thought-Leaders in Inflammatory Bowel Diseases
3. Skyscape Offers Medical Professionals Real Time Clinical Decision Application on Google Android
4. Clinical trial advances new approach to re-sensitizing breast cancer
5. HealthWyse Clinical and Financial Point of Care Software Addresses OASIS-C Regulations and More
6. Drug Information Association (DIA) Announces New Clinical Safety and Pharmacovigilance Certificate Program
7. Most Antidepressants Miss Key Target of Clinical Depression
8. Quantros(TM) Unveils Clinical Cafe, Social Networking Website for Healthcare Professionals Focused on Safety, Quality and Compliance
9. Pharmacyclics, Inc. Reports Interim Safety and Clinical Data from a Phase I/II Clinical Trial of its Oral HDAC Inhibitor PCI-24781 in Lymphoma at the American Society of Hematology Annual Meeting
10. Reportlinker Adds Emerging Clinical Trial Locations - India: Market Dynamics and the Changing Healthcare and Regulatory Environment
11. UM Clinical Research Building awarded prestigious LEED Building Certification
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/16/2017)... ... ... an inspirational story for those shackled by the chains of a broken life. “God ... and a woman of great faith and wisdom. She is a great motivational speaker. ... and raised in Vero Beach, Florida and has dedicated her life and ministry to letting ...
(Date:8/15/2017)... ... 2017 , ... The first study to report that overall survival was extended ... the team’s findings now published online ahead of print in the Journal of Clinical ... Marrow Transplant Program at Roswell Park Cancer Institute, was principal investigator for one of ...
(Date:8/15/2017)... , ... August 15, 2017 , ... Progressive Dental, a ... a spot on the 2017 Fast 50 list of Fastest Growing Companies in Tampa ... seven county area who has shown three consecutive years of growth. For this year’s ...
(Date:8/15/2017)... ... August 15, 2017 , ... Dr. Timothy ... patient’s periodontal disease . This information can be used to develop patient-specific ... , The two salivary diagnostic tests, named MyPerioPath® and MyPerioID® are offered by ...
(Date:8/15/2017)... ... August 15, 2017 , ... Rejuvenate ... of services. FDA-cleared CoolSculpting is the world’s most popular non-invasive fat reduction treatment, ... CoolSculpting can reduce fat cells in almost any area of the body, including ...
Breaking Medicine News(10 mins):
(Date:8/8/2017)... Second-quarter 2017 revenues of $876 ... from continuing operations Second-quarter ... $110 million Second-quarter 2017 ... Second-quarter 2017 adjusted diluted ... percent to $0.93 Second-quarter ...
(Date:8/7/2017)... 7, 2017  Diplomat Pharmacy, Inc. (NYSE: DPLO), the nation,s ... ended June 30, 2017.  All comparisons, unless otherwise noted, are ... Second Quarter 2017 Highlights include: ... million, an increase of 3.5% Total prescriptions ... margin of 7.5% versus 7.6% Gross ...
(Date:8/3/2017)... , Aug. 3, 2017  Opioid addiction and other ... up healthcare costs and threatening outcomes, were problems taken ... and IVD industry that support them, met this week. ... researcher said that drugs of abuse, procalcitonin and acute ... at the organization,s 69th meeting in San ...
Breaking Medicine Technology: